Marinopyrrole A (also known as Maritoclax) is a natural product and a selective antagonist of Mcl-1 with anticancer activity. Mcl-1 is a member of the anti-apoptotic Bcl-2 family of proteins, which also includes the well-validated drug targets Bcl-2, Bcl-X(L), and Mcl-1. While ABT-737 and its orally active analog ABT-263 are the most potent and specific inhibitors to date that bind Bcl-2 and Bcl-X(L) with high affinity but have a much lower affinity for Mcl-1, they are not very effective as single agents in certain cancer types due to elevated levels of Mcl-1. However, by binding to and targeting Mcl-1 for proteasomal degradation, Marinopyrrole A can overcome ABT-737 resistance. Maritoclax has an IC50 of 10.1 μM, which is sufficient to interfere with the interaction between Bim and Mcl-1. Maritoclax's pro-apoptotic activity is connected to the way mariopyrrole A induces Mcl-1 degradation through the proteasome system. ABT-737's effectiveness against hematologic malignancies, such as K562, Raji, and multidrug-resistant HL60/VCR, is significantly increased by Marinopyrrole A by 60- to 2000-fold at 1-2 μM, selectively killing Mcl-1-dependent leukemia cells but not Bcl-2 or Bcl-XL-dependent leukemia cells.
Physicochemical Properties
Molecular Formula | C22H12CL4N2O4 | |
Molecular Weight | 510.15 | |
Exact Mass | 507.955 | |
CAS # | 1227962-62-0 | |
Related CAS # |
|
|
PubChem CID | 24797083 | |
Appearance | Light yellow to yellow solid | |
Density | 1.6±0.1 g/cm3 | |
Boiling Point | 732.4±60.0 °C at 760 mmHg | |
Flash Point | 396.7±32.9 °C | |
Vapour Pressure | 0.0±2.5 mmHg at 25°C | |
Index of Refraction | 1.708 | |
LogP | 6.91 | |
Hydrogen Bond Donor Count | 3 | |
Hydrogen Bond Acceptor Count | 4 | |
Rotatable Bond Count | 5 | |
Heavy Atom Count | 32 | |
Complexity | 715 | |
Defined Atom Stereocenter Count | 0 | |
SMILES | OC1=CC=CC=C1C(C2=C(N3C(C(C4=CC=CC=C4O)=O)=CC(Cl)=C3Cl)C(Cl)=C(Cl)N2)=O |
|
InChi Key | QYPJBTMRYKRTFG-UHFFFAOYSA-N | |
InChi Code | InChI=1S/C22H12Cl4N2O4/c23-12-9-13(19(31)10-5-1-3-7-14(10)29)28(22(12)26)18-16(24)21(25)27-17(18)20(32)11-6-2-4-8-15(11)30/h1-9,27,29-30H | |
Chemical Name | [4,5-dichloro-1-[4,5-dichloro-2-(2-hydroxybenzoyl)-1H-pyrrol-3-yl]pyrrol-2-yl]-(2-hydroxyphenyl)methanone | |
Synonyms |
|
|
HS Tariff Code | 2934.99.9001 | |
Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
Targets | Mcl-1 (IC50 = 10.1 μM) |
ln Vitro | Maritoclax induces Mcl-1 degradation via the proteasome system, which is associated with the pro-apoptotic activity of maritoclax. Maritoclax selectively kills Mcl-1-dependent leukemia cells but not Bcl-2 or Bcl-XL-dependent leukemia cells, and at concentrations of 1-2 M, it significantly increases the effectiveness of ABT-737 against hematologic malignancies like K562, Raji, and multidrug-resistant HL60/VCR. Maritoclax has an IC50 value of 10.1 M and inhibits the binding of biotin-labeled Bim-BH3 peptide to GST-Mcl-1 in a dose-dependent manner. However, at concentrations up to 80 M, it does not inhibit the binding of Bim-BH3 peptide to GST-Bcl-XL. By causing the protein Mcl-1 to degrade, maritoclax activates caspase-3. Treatment with maritoclax markedly reduces the half-life of Mcl-1 to ∼0.5 h as compared with nearly 3 h in control cells. Maritoclax appears to have no impact on Mcl-1's (Ser159/Thr163) phosphorylation, indicating that it may cause Mcl-1 degradation independent of phosphorylation[1]. Against clinically important hospital- and community-acquired MRSA strains, Marinopyrrole A exhibits potent concentration-dependent bactericidal activity. (at >20× MIC)[2] Marinopyrrole A exhibits only minor toxicity to mammalian cell lines. Maritoclax sensitivity depends on the type of cell. In HeLa, HEK293, or MEF cells, it is useless. Maritoclax is not a substrate for drug efflux caused by p-gp[3]. |
ln Vivo | Maritoclax administration at 20 mg/kg/d intraperitoneally causes significant U937 tumor shrinkage as well as a 36% tumor remission rate in athymic nude mice, without apparent toxicity to healthy tissue or circulating blood cells[3]. |
Cell Assay | For 12 hours, DMSO, 2 μM maritoclax alone or in combination with 1 M MG132 are applied to K562 cells expressing Mcl-1-IRES-BimEL. Protease inhibitors are added to 1% Chaps buffer, which is used to lyse cells (1% Chaps, 150 mM NaCl, 10 mM Hepes, pH 7.4). 350 g of protein-containing cell lysates are incubated with either control pre-immune serum or 4 μl of rabbit anti-Mcl-1 antiserum in 250 μl of the same lysis buffer at 4 °C for an entire night on a rotator. Adding 20 l of protein A-Sepharose beads for 3 hours at 4 °C, followed by 30 seconds of centrifugation at 6,000 rpm, is how immunoprecipitates are collected. |
Animal Protocol |
Female athymic nude (NCI Athymic NCr-nu/nu 01B74) mice 20 mg/kg i.p. |
References |
[1]. Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J Biol Chem. 2012 Mar 23;287(13):10224-35. [2]. Pharmacological properties of the marine natural product marinopyrrole A against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2011 Jul;55(7):3305-12. [3]. The selectivity of Marinopyrrole A to induce apoptosis in MCL1high BCL2low expressing myeloma cells is related to its ability to impair protein translation. Br J Haematol. 2016 Aug 14. [4]. Purported Mcl-1 inhibitor marinopyrrole A fails to show selective cytotoxicity for Mcl-1-dependent cell lines. Cell Death Dis. 2013 Oct 24;4:e880. |
Additional Infomation | (-)-marinopyrrole A is a member of the class of pyrroles that is 1'H-1,3'-bipyrrole substituted by four chloro groups at positions 4, 4', 5 and 5' and two 2-hydroxybenzoyl moieties at positions 2 and 2'. It is isolated from Streptomyces sp.CNQ-418 and exhibits cytotoxic and antibacterial activities. It has a role as an antimicrobial agent, an antibacterial agent, an antineoplastic agent, a marine metabolite and a bacterial metabolite. It is a member of pyrroles, an organochlorine compound, a member of phenols and an aromatic ketone. |
Solubility Data
Solubility (In Vitro) |
|
|||
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.90 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (4.90 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (4.90 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.9602 mL | 9.8010 mL | 19.6021 mL | |
5 mM | 0.3920 mL | 1.9602 mL | 3.9204 mL | |
10 mM | 0.1960 mL | 0.9801 mL | 1.9602 mL |